Komori
Changes in Officers4584Kidswell Bio CorporationPharmaceuticals

Notice Regarding Personnel Changes

Osuka Nao (大須賀 奈緒)'s position changed from General Manager, Corporate Strategy Division, to Executive Officer and Deputy Head of the Corporate Strategy Division. The Representative Director and President will continue to serve concurrently as Executive Officer and Head of the Corporate Strategy Division.

Worth reading
30Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 29 June 2026

Incoming appointee

1 item
Scheduled Appointment Date29 June 2026 (effective as of today)
Osuka Nao (大須賀 奈緒)
Previous positionGeneral Manager, Corporate Strategy Division
New positionExecutive Officer, Deputy Head of the Corporate Strategy Division
Reason for change

To strengthen coordination between the corporate and R&D strategies as part of the reorganization of the R&D structure and other operations, thereby enhancing the organizational management functions of the Corporate Strategy Division.

Details of organizational changes

Reorganization of the R&D structure and other operations, and enhancement of the organizational management functions of the Corporate Strategy Division

Who is moving to which position
ItemDetails
Resolution date29 June 2026
Scheduled Appointment Date29 June 2026 (effective as of today)
Name of appointeeOsuka Nao (大須賀 奈緒)
Appointee's new positionExecutive Officer, Deputy Head of the Corporate Strategy Division
Appointee's previous positionGeneral Manager, Corporate Strategy Division
Reason for changeTo strengthen coordination between the corporate and R&D strategies as part of the reorganization of the R&D structure and other operations, thereby enhancing the organizational management functions of the Corporate Strategy Division.
Details of organizational changesReorganization of the R&D structure and other operations, and enhancement of the organizational management functions of the Corporate Strategy Division
Items this document does not state (14)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen coordination between the corporate and R&D strategies and enhance the organizational management functions of the Corporate Strategy Division, in connection with the reorganization of the R&D structure and other operations based on the selection of candidates for director positions, organizational changes and personnel changes dated 14 May 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Personnel Changes | Kidswell Bio Corporation (4584) timely disclosure | Komori